FDA approves first gene therapy for genetic hearing loss
Summary
The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss
Description
The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source